Financial Analysis: Vertex Pharmaceuticals, Inc (VRTX)’s Ratios Unveil Key Insights

Kevin Freeman

Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.

As of close of business last night, Vertex Pharmaceuticals, Inc’s stock clocked out at $408.85, up 1.15% from its previous closing price of $404.21. In other words, the price has increased by $1.15 from its previous closing price. On the day, 1.64 million shares were traded. VRTX stock price reached its highest trading level at $410.995 during the session, while it also had its lowest trading level at $403.59.

Ratios:

To gain a deeper understanding of VRTX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 16.40 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 29.95. For the most recent quarter (mrq), Quick Ratio is recorded 2.16 and its Current Ratio is at 2.52. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.09.

Wells Fargo Upgraded its Equal Weight to Overweight on August 06, 2025, while the target price for the stock was maintained at $460.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 02 ’25 when Biller Jonathan bought 694 shares for $404.21 per share.

Bhatia Sangeeta N. sold 266 shares of VRTX for $102,860 on Aug 27 ’25. The Director now owns 4,565 shares after completing the transaction at $386.69 per share. On Aug 27 ’25, another insider, Bhatia Sangeeta N., who serves as the Director of the company, bought 266 shares for $386.69 each.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRTX now has a Market Capitalization of 104825323520 and an Enterprise Value of 99969916928. As of this moment, Vertex’s Price-to-Earnings (P/E) ratio for their current fiscal year is 29.22, and their Forward P/E ratio for the next fiscal year is 19.86. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.20 while its Price-to-Book (P/B) ratio in mrq is 6.10. Its current Enterprise Value per Revenue stands at 8.755 whereas that against EBITDA is 20.821.

Stock Price History:

The Beta on a monthly basis for VRTX is 0.35, which has changed by -0.10204035 over the last 52 weeks, in comparison to a change of 0.16766965 over the same period for the S&P500. Over the past 52 weeks, VRTX has reached a high of $519.88, while it has fallen to a 52-week low of $362.50. The 50-Day Moving Average of the stock is 1.69%, while the 200-Day Moving Average is calculated to be -8.30%.

Shares Statistics:

It appears that VRTX traded 1.77M shares on average per day over the past three months and 2042890 shares per day over the past ten days. A total of 256.29M shares are outstanding, with a floating share count of 255.62M. Insiders hold about 0.30% of the company’s shares, while institutions hold 95.29% stake in the company. Shares short for VRTX as of 1757894400 were 4053668 with a Short Ratio of 2.30, compared to 1755216000 on 3700693. Therefore, it implies a Short% of Shares Outstanding of 4053668 and a Short% of Float of 1.78.

Earnings Estimates

. The current assessment of Vertex Pharmaceuticals, Inc (VRTX) involves the perspectives of 22.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is $4.92, with high estimates of $5.29 and low estimates of $4.54.

Analysts are recommending an EPS of between $18.83 and $16.61 for the fiscal current year, implying an average EPS of $18.02. EPS for the following year is $20.19, with 23.0 analysts recommending between $23.32 and $18.31.

Revenue Estimates

In. The current quarter, 26 analysts expect revenue to total $3.05B. It ranges from a high estimate of $3.14B to a low estimate of $2.94B. As of. The current estimate, Vertex Pharmaceuticals, Inc’s year-ago sales were $2.77BFor the next quarter, 26 analysts are estimating revenue of $3.21B. There is a high estimate of $3.29B for the next quarter, whereas the lowest estimate is $3.1B.

A total of 30 analysts have provided revenue estimates for VRTX’s current fiscal year. The highest revenue estimate was $12.13B, while the lowest revenue estimate was $11.89B, resulting in an average revenue estimate of $11.99B. In the same quarter a year ago, actual revenue was $11.02BBased on 28 analysts’ estimates, the company’s revenue will be $13.21B in the next fiscal year. The high estimate is $15.35B and the low estimate is $11.94B.

DwinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.